Tuesday, April 02, 2024
Baxter International, known for its advancements in infusion therapies and technologies, has announced the FDA clearance of its Novum IQ large volume infusion pump (LVP) along with the Dose IQ Safety Software. This clearance signifies a significant step forward in Baxter's commitment to enhancing infusion therapy through innovation.
Heather Knight, Executive Vice President and Group President, Medical Products and Therapies at Baxter, emphasized the patient-centric approach of the Novum IQ platform, highlighting its role in improving care delivery. Knight stated, “Our primary goal is to provide our customers, clinicians, and patients with increased efficiency, safety, and informed decision-making opportunities. The Novum IQ platform marks a significant evolution in how connected and intelligent infusion therapy can revolutionize care delivery.”
The Novum IQ Infusion Platform integrates user experience across its LVP and SYR pumps, streamlining non-critical tasks and allowing clinicians to prioritize patient care. Key features include:
Baxter’s Novum IQ LVP facilitates the administration of high-volume infusions at faster rates, while Novum IQ SYR supports precise delivery of small amounts of fluid, often in pediatric or anesthesia care settings. Both Novum IQ LVP and SYR are now available for order in the U.S. Baxter plans to further expand the platform through ongoing product development and additional regulatory submissions.
Source: baxter.com
